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Abstract
Purpose: Current clinical measurements for tumor treatment efficiency rely often on changes in
tumor volume measured as shrinkage by CT or MRI, which become apparent after multiple lines
of treatment and pose a physical and psychological burden on the patient. Detection of therapy-
induced cell death in the tumor can be a fast measure for treatment efficiency. However, there
are no reliable clinical tools for detection of tumor necrosis. Previously, we studied the necrosis
avidity of cyanine-based fluorescent dyes, which suffered long circulation times before tumor
necrosis could be imaged due to low hydrophilicity. We now present the application of
radiolabeled 800CW, a commercially available cyanine with high hydrophilicity, to image tumor
necrosis in a mouse model.
Procedures: We conjugated 800CW to DOTA via a PEG linker, for labeling with single-photon
emission-computed tomography isotope indium-111, yielding [111In]In-DOTA-PEG4-800CW. We
then investigated specific [111In]In-DOTA-PEG4-800CW uptake by dead cells in vitro, using both
fluorescence and radioactivity as detection modalities. Finally, we investigated [111In]In-DOTA-
PEG4-800CW uptake into necrotic tumor regions of a 4T1 breast tumor model in mice.
Results: We successfully prepared a precursor and developed a reliable procedure for labeling
800CW with indium-111. We detected specific [111In]In-DOTA-PEG4-800CW uptake by dead
cells, using both fluorescence and radioactivity. Albeit with a tumor uptake of only 0.37%ID/g at
6 h post injection, we were able to image tumor necrosis with a tumor to background ratio of 7:4.
Fluorescence and radioactivity in cryosections from the dissected tumors were colocalized with
tumor necrosis, confirmed by TUNEL staining.
Conclusions: [111In]In-DOTA-PEG4-800CW can be used to image tumor necrosis in vitro and
in vivo. Further research will elucidate the application of [111In]In-DOTA-PEG4-800CW or other
radiolabeled hydrophilic cyanines for the detection of necrosis caused by chemotherapy or other
anti-cancer therapies. This can provide valuable prognostic information in treatment of solid tumors.
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Introduction
Necrotic tissue is typically found in pathophysiological
conditions and is absent in healthy individuals. Necrosis is in
most cases caused by lack of oxygen and characterized by loss
of cell membrane integrity. In many pathological situations,
necrosis can also be programmed like necroptosis, ferroptosis,
parthanathos, and pyroptosis [1]. Most prominent examples of
necrosis occur after myocardial infarcts and strokes, where the
affected tissues turn necrotic due to ischemic stress [2]. In
addition, solid tumors often have poor vascular quality,
resulting in reduced concentration of oxygen and nutrients in
the tumor center. This occurs even more in aggressively
growing solid tumors as the formation of new blood vessels
(angiogenesis) cannot keep up with the fast growth of the
tumor. Typically, the amount of necrosis per tumor volume is a
strong measurement for the aggressiveness of the tumor and
used by pathologists to determine the severity of the disease [3–
5]. In addition to intrinsic tumor necrosis, tumors develop
necrotic tissue when affected by anti-cancer chemotherapy or
radiotherapy [6].
The clinical evaluation of treatment response is normally
done using CT or MRI based on the RECIST criteria, which
endow clinical decision making on either treatment continua-
tion or alternation [7]. However, these guidelines have
significant shortcomings. The guidelines state that solid tumor
treatment response should be determined by means of tumor
size or volume reduction. However, this interpretation is prone
to human error, is time consuming, and often requires multiple
lines of treatment to become evident [8]. There is therefore an
unmet need for novel, time-resolved criteria for early assessing
the efficiency of cancer therapy treatment.
We and others have previously shown that the increase in
chemotherapy or radiotherapy-induced cell death, especially
necrosis, can be used as an early indicator for treatment
efficiency [9–12]. Effective chemotherapy will induce
significant tumor necrosis within days after a single line of
treatment, due to either programmed or secondary necrosis.
The latter is when massive apoptosis occurs and the few
tissue macrophages present are not able to timely remove the
apoptotic cells, which then become necrotic [6]. At the
moment, there are no appropriate clinical tools available that
allow noninvasive quantitative detection of tumor necrosis.
Such a tool could be a necrosis-avid contrast agent (NACA)
that specifically binds necrotic cells and can be traced in the
body using imaging techniques (e.g., MRI, PET, SPECT).
A frequently described NACA is hypericin, a natural
product and photodynamic agent isolated from St. John’s wort,
which binds to necrotic cells by an unknown mechanism.
Therefore, this property has been utilized to image necrosis in
various necrosis models (e.g., necrotic myocardium or tumor
necrosis models) by radiolabeling hypericin with iodine [13,
14]. However, hypericin has certain limitations such as poor
water solubility, formation of aggregates, and difficult synthe-
sis and it is photosensitive [15, 16]. Moreover, it can cause
significant drug interactions [17].
Our group demonstrated that a certain class of near-
infrared fluorescent (NIRF) cyanine dyes binds to denatured
cytoplasmic proteins from cells that lost their membrane
integrity. These can therefore be used for SPECT imaging of
necrosis, via a radiometal-chelation chemistry approach [9,
11]. However, the HQ class of cyanines that we have used
was thermally unstable and henceforth was conjugated with
the non-linear DTPA chelator. DTPA allows indium-111
chelation at room temperature, but other DTPA-radiometal
complexes have low in vivo stability [18]. Moreover, HQ-
class cyanines are hydrophobic, leading to long circulation
times before reaching the target tissue. This is a limiting
factor for clinical translation since it is preferable to image
shortly after administration.
Here, we describe radiolabeling of 800CW, a cyanine
with improved water solubility and NIRF properties com-
pared to HQ5 (785-nm excitation, 800-nm emission of
800CW; and 683-nm excitation, 701-nm emission of HQ5)
[9]. The more redshifted wavelength of 800CW, compared
to HQ4 and HQ5, has deeper tissue penetration of up to 1–
2 cm and is henceforth favorable for in vivo applications,
especially in small animals or in superficial tissues like skin,
breast, and head and neck in humans [19]. However, for
whole body imaging, a more quantitative imaging technol-
ogy is needed like nuclear imaging using PET or SPECT.
For this reason, we conjugated 800CW, via a polyethylene
glycol (PEG) linker to DOTA, a widely applied chelator in
the clinic for radiolabeling with SPECT-isotope indium-111
[18]. We first characterized and determined the purity of
DOTA-PEG4-800CW (1) by HPLC and mass spectrometry.
Thereafter, a reliable radiolabeling procedure was developed
and we tested in vitro necrosis-avidity of DOTA-PEG4-
800CW with and without indium-111 labeling. After
validation, indium-111–labeled 1 ([111In]In-DOTA-PEG4-
800CW, from here referred to as [111In]1) was tested in vivo
in the mouse 4T1 breast cancer model that spontaneously
develops tumor necrosis.
Materials and Methods
Materials
Reagents were purchased from Sigma-Aldrich (St. Louis,
MO, USA) unless stated otherwise. Solvents were purchased
from Honeywell Riedel-de-Haën™ (Seelze, Germany).
800CW-N-hydroxysuccinimide ester (2) was purchased from
Westburg BV (Leusden, The Netherlands). DOTA-PEG4-
NH2 (3) was purchased from Chematech (Dijon, France).
[ 1 1 1 I n ] I nC l 3 f r om Ma l l i n ck r od t BV (Pe t t e n ,
The Netherlands). 4T1-Luc2 cells were purchased from
PerkinElmer (Boston, MA, USA). Cell culture media was
obtained from Sigma-Aldrich (St. Louis, MO, USA) or
Gibco Life Technologies (Waltham, MA, USA). ESI-MS
analysis was performed on a TSQ Quantum Ultra system
equipped with a Surveyor Autosampler Plus and MS Pump
Plus from Thermo Fisher Scientific (San Jose, CA, USA).
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HPLC analysis was performed on a system from Waters
(Milford, MA, USA) with a quaternary pump, a 2998 PDA
detector, a radio detector consisting of a NaI crystal detector
with a Canberra Osprey-DTB, and dedicated software.
Solvent A was water + 0.1 % v/v TFA, and solvent B was
ACN + 0.1 % v/v TFA. HPLC method A is Gemini C18
semi-preparative column (10 × 250 mm, 5 μm, Waters) and
a gradient profile of 0–1 min 20 % B in A, 1–25 min to
30 % B at a flow rate of 3.0 ml/min. HPLC method B is
Symmetry C18 analytical column (4.6 × 250 mm, 5 μm,
Waters) and a gradient profile of 0–1 min 10 % B, 1–20 min
towards 60 % B at a flow rate of 1.0 ml/min. HPLC method
C is Symmetry C18 analytical column (4.6 × 250 mm, 5 μm,
Waters) and a gradient profile of 0–1 min 22 % B, 1–20 min
towards 51 % B (solvent A was 0.2 M Tris-HCl buffer
pH 8.5 + 10 % MeOH and solvent B was MeOH) at a flow
rate of 1.0 ml/min. Autoradiography was performed using
super resolution phosphor screens and a Cyclone® Plus
system (Perkin Elmer, Waltham, MA, USA). NIRF imaging
was performed on an Odyssey flatbed scanner system
(800 nm channel, laser intensity 5.0; Li-Cor, Lincoln, NE,
USA). Bioluminescence imaging (BLI) was performed in an
IVIS-Spectrum imager (Perkin Elmer). SPECT/CT images
were obtained with a VECTor-5, equipped with a high-
sensitivity 3.0-mm pinhole collimator (MILabs, Utrecht,
The Netherlands). The mages were analyzed with Pi-Mod
(version 3.901) and visualized in VivoQuant (version 2.50,
patch 3). Activity was accurately quantified on a Wizard 3″,
1480 γ-counter (Perkin Elmer). Histochemical dead cell
staining was performed using the DeadEnd™ Colorimetric
TUNEL System (Promega, Madison, WI, USA) and subse-
quent imaging on a NanoZoomer 2.0HT digital slide scanner
(Hamamatsu, Hamamatsu City, Japan).
Synthesis DOTA-PEG4-800CW (1)
Compound 2 (5.0 mg, 4.4 μmol) was dissolved in DMSO
(50 μl) and added to a mixture of DOTA-PEG4-NH2 (3,
3.1 mg, 3.8 μmol) and DiPEA (1.78 μl, 10.1 μmol) in
DMSO (200 μl). The resulting solution was stirred overnight
at room temperature. Subsequently, the mixture was directly
purified over semi-preparative HPLC, method A (tR 14 min),
yielding a green solid (4.1 mg, 55 %). The purity was 9
99 % as determined by HPLC, method B (tR 10.1 min,
Supplementary data 1). ESI-MS: m/z calculated for
C72H103N8O25S4
+ was 1607.59. m/z found was 802.67
[M-3H]2−; 534.75 [M-4H]3−.
Synthesis Reference Compound in-DOTA-PEG4-
800CW (Nat.In-1)
Compound 1 (430 μg, 250 nmol) was added into a conical
vial, and quenchers were added to mimic reaction conditions
of radiolabeling (gentisic acid and sodium ascorbate with a
final concentration of 3.5 mM). The reaction was buffered to
pH 4–4.5 with sodium acetate (53.6 μl, 2.5 M) and diluted
with Milli-Q water to a final reaction volume of 135 μl.
Then, InCl3 (375 nmol, native indium ICP standard in
0.05 M HCl) was added, and the sealed vial was heated to
70 °C for 30 min. The vial was allowed to cool to room
temperature and DTPA (4 mM, 5 μl) was added to complex
remaining indium. The conversion yield was 9 99 % as
determined by HPLC, method B (tR 9.5 min, Supplementary
data 2). ESI-MS: m/z calculated for C72H100N8O25S4In
+ was
1719.47. m/z found was 860.19 [M+H]2+.
Radiolabeling
Into a conical vial, gentisic acid and sodium ascorbate (both
50 mM in 10 μl) were added to 1 (1.4/14/70 μg; 0.8/8.0/
40 nmol; for low, medium, or high dose, respectively) to
prevent radiolysis [20]. The reaction was buffered to pH 4–
4.5 with sodium acetate (1 μl, 2.5 M) and diluted with Milli-
Q water for a final reaction volume of 135 μl. Then,
[111In]InCl3 (80 MBq) was added and the sealed vial was
heated to 70 °C for 30 min. The vial was cooled to room
temperature for 5 min, and DTPA (4 mM, 5 μl) was added.
Radiochemical purity (RCP) of [111In]1 was 9 95 % as
determined by HPLC, method C (tR 14.1 min). Radiochem-
ical yield was determined by an instant thin-layer chroma-
tography (iTLC-SG paper, Aligant, eluent: 10 % w/v NH4Ac
to MeOH 9:1, [111In]In-DTPA eluted to top of paper and
[111In]1 remained at the baseline).
In Vitro Dead/Alive Cell Uptake Assay Fluores-
cence
4T1-Luc2 cells were cultured in RPMI-1640 medium
containing 10 % fetal bovine serum and 1 % penicillin at
37 °C under a humidified atmosphere with 5 % CO2. The
cells were seeded in a black 96-well plate with transparent
bottom (typically 1.0 × 104 cells per well) and grown until
70–80 % confluency. Then, from half of the wells, the
medium was removed, the cells were killed with EtOH (4 μl,
70 %) and washed once with PBS. The live cells in the other
half of the wells were washed with PBS, and subsequently,
all cells were incubated for 15 min with or without 800CW
or it conjugates (100 nM in culture medium) as indicated.
The cells were washed thrice with PBS, fixated with 4 %
formalin, and the whole plate was imaged on the Odyssey.
This experiment was performed in triplicate.
In Vitro Dead/Alive Cell Uptake Assay Radioac-
tivity
4T1-Luc2 cells were seeded in two 12-well plates (1.0 × 105
cells per well) and grown until 70–80 % confluency. After
incubation, the medium was removed from half of the wells,
after which the cells were killed with EtOH (50 μl, 70 %)
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and washed once with PBS. The live cells were washed with
PBS, and subsequently, all cells were incubated for 1 h at
37 °C with or without the radiotracers (3.3 MBq/nmol,
100 nM in 400 μl culture medium). Then, the cells of one
plate were washed twice with PBS, detached with 1.0 M
NaOH, and collected in tubes for γ-counting. The cells of the
other plate were washed twice with PBS; the whole plate
was imaged on a phosphor screen (2 h) and the Odyssey.
This experiment was performed in triplicate.
Animals
All animal experiments were approved by the Animal
Welfare Committee and conducted in accordance with
accepted guidelines. Female BALB/cAnNRj-nude mice (6
to 8 weeks old) were housed in ventilated cages in groups of
four to six mice and were provided standard laboratory
animal food pellets and water ad libitum. A week after
arrival, 1.0 × 104 4T1-Luc2 cells suspended in 15 μl
matrigel: PBS (1:1) were injected bilaterally on the
shoulders. Tumor growth was monitored every 3 days with
a caliper. After 2 weeks, mice were injected with D-luciferin
(150 mg/kg, i.p. injection). Ten minutes later, BLI was
performed for 30 s with an open filter under isoflurane
anesthesia (4 % induction, 1.5 to 2 % maintenance in 100 %
O2). All groups consisted of three mice with bilateral tumors.
SPECT Imaging
Tumor-bearing mice received an intravenous injection of
[111In]1 (20 MBq, labeled to 0.2, 2, or 10 nmol, 200 μl PBS)
in the tail vein. At 6 and 24 h post injection (h.p.i.), SPECT/
CT imaging was performed under isoflurane anesthesia,
while the body temperature was maintained constant. Static
images of the 5-cm axial field of view were obtained over a
total scan time of 28 min and 20 s, followed by a 2-min full
body CT. Dynamic scans were obtained over a total duration
of 1 h with 30 timeframes, directly after injection of [111In]1.
Acquired images were reconstructed using SR-OSEM
with 9 iterations and 128 subsets on a 36 × 36 × 35 mm
matrix with 0.80 × 0.80 mm isotropic voxels. The images
were further analyzed in Pi-Mod and VivoQuant. Regions of
interest were manually drawn around the tumors, heart, and
muscle. Subsequently, the percentage of injected dose (%ID)
and the tumor to background ratio (TBR) were determined.
Urine Analysis
Excreted urine was collected at 1 h.p.i. and frozen in liquid
nitrogen. The urine was then thawed, precipitated with an
equal volume of ACN, centrifuged at rcf: 16100×g for
15 min, and the supernatant was analyzed by radio-HPLC.
As a control for the processing, 1 MBq of the NACA in PBS
was treated in a similar way as the urine.
Ex vivo Analysis
After imaging, the blood, tumors, skin, pancreas, liver,
spleen, small intestines, colon, ovaries, kidneys, lungs, heart,
muscle, bone, lymph nodes, and brain were collected and
weighted, and activity was accurately quantified in a γ-
counter. After counting, the tumors were frozen in liquid
nitrogen and adjacent 10-μm cryosections of tumor centers
were prepared for autoradiography, NIRF imaging, and
TUNEL staining.
Statistics
All data are expressed as the mean ± standard deviation
(SD). Significance was determined with F-test and two-
tailed t test in Microsoft Excel 2010.
Results
Synthesis and Radiolabeling
Precursor 1 was successfully synthesized via an amide
coupling reaction between 2 and 3 (Fig. 1). After purifica-
tion, 4.1 mg (55 % yield) of precursor was isolated as a
green solid, with a purity of 9 99 % (HPLC), and was stored
in titrated aliquots of 15.6 nmol at − 20 °C.
The RCP and RCY of [111In]1 were 9 95 % with molar
activities achieved up to 200 MBq/nmol. The antioxidant
gentisic acid and ascorbic acid in the reaction mixture
stabilized radiochemical purity. After 2 days at room
temperature (10 MBq/nmol/200 μl), RCP was 9 95 %
(Supplementary data 3). All in vitro and in vivo experiments
were executed within 3 h after radiolabeling.
In Vitro Dead/Alive Cell Uptake
We further examined the effect of the metal chelation and
indium labeling on the necrosis avidity of 800CW in dead or
alive 4T1-Luc2 cells. Based on fluorescent signal from the
cells after washing, the uptake of 800CW and its conjugates
was determined (Fig. 2a).
The following conditions were tested: In-DOTA-PEG4-
800CW (Nat.In-1), labeled with non-radioactive indium;
DOTA-PEG4-800CW which was heated at 70 °C for
30 min (1a) [20], untreated 1, 800CW-carboxylate (4),
DOTA-PEG4-NH2 (3) as a negative control, and medium
for background subtraction. The experiment was performed
in triplicate (Fig. 2a). Based on the fluorescent signal, we
found that neither the procedures required for radiolabeling
nor the indium complexation of 800CW had a significant
effect on uptake by dead cells (Fig. 2b).
Later, we determined the [111In]1 uptake by dead cells
and used [111In]In-DOTA-PEG4-NH2 ([
111In]3) as a nega-
tive control. The wells were washed, and the whole plate
was imaged on a phosphor screen for visualization of the
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radioactivity and on the Odyssey (Fig. 2c) for quantification
of the fluorescence. The fluorescent signal from the dead
cells was a 67-fold stronger than that from the live cells
(Fig. 2d). As expected, no fluorescence signal was observed
from the [111In]3-treated wells. Simultaneously, a second
plate was prepared, from which the cells were collected from
the wells after incubation and washing. The radioactivity
was measured in a γ-counter for accurate quantification of
the radioactivity uptake (Fig. 2e). There was no uptake of
[111In]3 by dead or alive cells, however a 23-fold higher
uptake of [111In]1 by dead cells as compared to live cells.
SPECT Imaging and Ex Vivo Analysis
[111In]1 was administrated in female nude mice inoculated
with 4T1-Luc2 breast cancer cells, which develop rapidly
growing tumors with spontaneous necrotic cores. The
necrotic core was first confirmed by BLI since 4T1-Luc2
cells express luciferase. As a result, necrotic tumors showed
a ring-shaped BLI signal from their viable outer rim and a
much lower signal from the center (Supplementary data 4)
[9].
In the first in vivo experiment, we evaluated the dose
range in which the tumors could be imaged. Therefore, three
doses of 1 (i.e., 0.2 nmol, 2.0 nmol, and 10 nmol; from here
referred to as low, medium, and high dose) with a constant
amount of radioactivity (i.e., 20 MBq) per injection were
tested. At 6 and 24 h.p.i., SPECT/CT imaging was
performed. Then, the animals were euthanized and the
organs and tumors were collected for biodistribution and
histological analysis.
The uptake in the tumors and kidneys were clearly visible
on SPECT images at 6 and 24 h.p.i (Fig. 3 a and b). The
SPECT signal from the tumors was quantified and showed
no significant difference in the total counts between high and
medium dose at 6 h.p.i. On the other hand, the total counts
were significantly lower in the low-dose group (44 kBq/ml)
compared to the high-dose group (61 kBq/ml, P 0 0.03,
Fig. 3c). However, no major differences were observed in
Fig. 1 Synthesis of DOTA-PEG4-800CW. a DOTA-PEG4-NH2 (3), DiPEA, DMSO, rt., 16 h, yield 55 %. b NaAc, gentisic acid,
sodium ascorbate, H2O, 70 °C, 30 min, RCP 9 98 %.
Fig. 2 In vitro dead cell binding of 800CW. a Dead or alive 4T1-Luc2 cells in a 96-well plate, treated with either Nat.In-1, 1a
(heated at 70 °C for 30 min), 1, 4, 3, or culture medium. b Fluorescent signal from a, black bars indicate signal from dead cells
and white bars indicate signal from alive cells (n 0 9). c Dead or alive 4T1-Luc2 cells in a 12-well plate, treated with either [111In]1
or [111In]3. The 800-nm channel is depicted in green, and the 700-nm channel is depicted in red, and below the corresponding
autoradiography signal. d, e Fluorescent signal (d) and bound activity (e) from wells in c. ns 0 no significant difference.
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%ID between the three doses at 6 h.p.i. (Fig. 3d). At
24 h.p.i, no significant differences in either total counts or
%ID was seen between the three doses. Similarly, the
biodistribution studies also showed no significant differ-
ences in %ID/g between the three dose groups at 24 h.p.i.
(Fig. 4a), confirming these results. Even though the overall
uptake in the tumors was low, the tumors were clearly
visible on SPECT images due to high TBRs (Fig. 3e). The
TBR for the low-dose group was the highest (10:3),
followed by medium-dose group (7:4), and high-dose group
(4:2, P 0 0.087). At 24 h.p.i., however, there were no
significant differences between the three doses (Fig. 3c–e).
The uptake of the NACA into the necrotic regions of the
extracted tumor was confirmed by autoradiography, NIRF
imaging, and TUNEL staining of the cryosections (Fig. 3f).
Next, we evaluated the optimal time-point for imaging.
The NACA uptake in %ID/g was determined at 3, 6, 24, 48,
and 72 h.p.i. At each time-point, mice were euthanized and
the organs were collected to determine the biodistribution of
the NACA (Fig. 4). The tumor uptake did not increase over
time, and no significant differences were observed between
time-points. However, it can be noted that the NACA is
rapidly excreted from the body with 3%ID/g left in the
kidneys after 3 h. As a result, the tumor to blood ratios
increased over time, up to 29:7 at 72 h.p.i. (Supplementary
data 5).
We performed dynamic scans of the first hour after
injection of the NACA, in which we observed renal
clearance of most of the NACA in the first recorded frame
recorded 0–5 min post injection (Supplementary data 6). At
1 h.p.i., urine was collected and analyzed by radio-HPLC
(method C, 0.2 MBq injected, recovery 9 95 %). We
observed that 9 98 % of the activity eluted at 14 min
indicating that the NACA was excreted intact (Fig. 5).
Discussion
In a previous publication using the cyanines HQ4, HQ5, and
800CW, we demonstrated that we can image tumor necrosis
in mice using whole body NIRF imaging techniques [9]. For
clinical translation, we conjugated HQ4 with DTPA and
radiolabeled it with indium-111 for SPECT imaging and
showed that tumor necrosis could be imaged with good
TBRs [11, 21]. However, we foresaw that HQ cyanines are
Fig. 3 SPECT/CT imaging with [111In]1. a, b Representative SPECT/CT image of a mouse injected with [111In]1 at 6 h.p.i. (a)
and 24 h.p.i. (b). The dotted lines indicate field of view of SPECT images. c Concentration of activity in tumor ROIs from SPECT
images in kBq/ml, n 0 6. d Activity in tumor, normalized injected dose tumor uptake %ID (n 0 6). e TBR (tumor to heart) from
SPECT signal, n 0 6. f Adjacent cryosections from a dissected tumor. From top to bottom: autoradiography, NIRF imaging, and
TUNEL staining.  for p G 0.05; ** for p G 0.01.
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sub-optimal for clinical translation because they are lipo-
philic and hence are cleared by the hepatic-intestinal route
and showed long blood circulation. Therefore, 9 24 h were
required for a good tumor to background ratio. This ratio is
in contrast to 800CW, which is a highly hydrophilic cyanine
that is cleared by the kidneys and has a good TBR after 3–
6 h [9]. Especially when using radiotracers, rapid clearance
is preferred to minimize radioactive exposure to the organs.
Therefore, in this study, we determined the use of 800CW as
a necrosis-specific probe for SPECT by radiolabeling with
indium-111. In order to do so, we conjugated 800CW with
DOTA, one of the most used chelators in the clinic. We
proceeded to test the necrosis avidity in vitro with our in-
house–developed dead cell assay. Based on the fluorescent
signal, the 800CW uptake by dead cells is not significantly
affected by conjugation with DOTA via a PEG4 linker and
subsequent chelation of indium. This is in line with the
previous findings that 800CW could image necrosis when
conjugated with small molecule probes [9]. Moreover, we
found that 800CW was not degraded by the heating,
required for radiolabeling.
From the in vivo imaging experiments, it was evident that
there was no significant difference in tumor uptake between
the tested doses. However, the TBR was greater in the group
that received a low dose (10:3) compared to medium dose
(7:4) and high dose (4:2). This confirms that even at low
doses it is feasible to image necrosis with 800CW. However,
we wanted to use the fluorescent signal, which could not be
detected at the low dose, for further confirmation. Hence, the
medium dose was selected for further experiments since a
clear fluorescent signal was obtained.
In order to increase the dose, while maintaining the
amount of activity injected (20 MBq) constant, the molar
activity was required to be reduced. The molar activity is an
important parameter that should be considered with radio-
pharmaceuticals that target receptors or proteins since there
is only a limited number of proteins available in the targeted
tissue. Decreasing the molar activity can result in a
saturation of the target protein, rendering a lower activity
uptake in the targeted tissue [22]. This effect is not observed
in the case of necrosis-avid cyanines. This could be due to
their binding to denatured cytosolic proteins, which are
highly abundant and unlikely to saturate [9].
Necrosis-targeting probes, such as hypericin, have been
successfully shown to target necrosis and also to deliver
local radionuclide therapy in the center of necrotic tumors
[14, 16]. However, certain limitations such as difficult
synthesis, poor water solubility, and toxicity effects have
been reported for these probes [15–17]. NIR cyanines like
800CW could be an interesting starting point for developing
novel clinical tools, since they have been applied in ample
preclinical and clinical applications. For instance, ICG, a
serum albumin-binding NIR cyanine, is the current golden
standard for visualizing tissue perfusion in the emerging
field of fluorescence-guided surgery [23]. Likewise, 800CW
has been applied in several clinical studies when conjugated
Fig. 4 Biodistribution of [111In]1. a Biodistribution at 24 h.p.i. of three different doses of [111In]1 (n 0 3). b Biodistribution of
[111In]1 (2 nmol, 20 MBq) at five different time points after injection (n 0 3).
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to a tumor-targeting molecule without any reports of toxicity
induced by the cyanine itself [24, 25].
As compared to [111In]In-DTPA-HQ4, [111In]1 has a
faster clearance from the blood, which is mainly accommo-
dated by the renal system. This is most likely because of the
higher water solubility of 800CW. As a result, the
background signal dropped rapidly and SPECT/CT imaging
could be performed at 6 h.p.i. With [111In]In-DTPA-HQ4,
imaging could only be performed 24 h.p.i. onwards. It
should also be noted that the tumor uptake of [111In]1 was
lower than that of [111In]In-DTPA-HQ4 but sufficient for
imaging the tumors [21].
Due to the rapid biokinetics, shorter lived radioisotopes
would be more suitable for imaging with 1. For instance, 1
could be labeled with PET-radionuclide gallium-68 [26].
Conclusions
We demonstrated that [111In]1 can be used to image tumor
necrosis in mice. It is rapidly excreted from the body, and
the tumors can be imaged at high contrast at early time
points after injection. We showed the uptake of [111In]1 into
spontaneous developing tumor necrosis in a mouse model
with 4T1-Luc2 breast cancer. Future studies should elucidate
whether [111In]1 can be used to image tumor necrosis, which
is induced by chemotherapy or other anti-cancer therapies.
Acknowledgements. This research is funded with grant 11089–2017/1 from
the Koningin Wilhelmina Foundation (KWF).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Open Access This article is licensed under a Creative Commons Attribution
4.0 International License, which permits use, sharing, adaptation, distribu-
tion and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons licence, and indicate if changes were made. The
images or other third party material in this article are included in the article's
Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://
creativecommons.org/licenses/by/4.0/.
References
1. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P,
Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-
Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA,
Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny
MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M,
Candi E, Carmona-Gutierrez D, Cecconi F, Chan FKM, Chandel NS,
Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM,
Conrad M, Cubillos-Ruiz JR, Czabotar PE, D’Angiolella V, Dawson
TM, Dawson VL, de Laurenzi V, de Maria R, Debatin KM,
DeBerardinis RJ, Deshmukh M, di Daniele N, di Virgilio F, Dixit
VM, Dixon SJ, Duckett CS, Dynlacht BD, el-Deiry WS, Elrod JW,
Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C,
Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA,
Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS,
Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin
PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN,
Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B,
Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW,
Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni
W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP,
Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM,
Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer
M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira
DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM,
Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues
CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L,
Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser
A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A,
Tsujimoto Y, Turk B, vanden Berghe T, Vandenabeele P, Vander
Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D,
Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W,
Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G
(2018) Molecular mechanisms of cell death: recommendations of the
nomenclature committee on cell death 2018. Cell Death Differ
25(3):486–541
2. Malhotra R, Lin Z, Vincenz C, Brosius FC (2001) Hypoxia induced
apoptosis via two independent pathways in Jurkat cells: differential
regulation by glucose. Am J Physiol Cell Physiol 281(5):C1596–
C1603
3. Lee SY, Ju MK, Jeon HM et al (2018) Regulation of tumor
progression by programmed necrosis. Oxid Med Cell Longev
2018:3537471. https://doi.org/10.1155/2018/3537471
Fig. 5 a HPLC chromatogram of [111In]1 from PBS. b HPLC
chromatogram of urine from mouse at 1 h.p.i.
Stroet M.C.M. et al.: In Vivo Evaluation of Indium-111–Labeled 800CW as a Necrosis-Avid Contrast Agent
4. Bredholt G, Mannelqvist M, Stefansson IM, Birkeland E, Bø TH,
Øyan AM, Trovik J, Kalland KH, Jonassen I, Salvesen HB, Wik E,
Akslen LA (2015) Tumor necrosis is an important hallmark of
aggressive endometrial cancer and associates with hypoxia, angiogen-
esis and inflammation responses. Oncotarget 6(37):39676–39691
5. Richards CH, Mohammed Z, Qayyum T, Horgan PG, McMillan DC
(2011) The prognostic value of histological tumor necrosis in solid
organ malignant disease: a systematic review. Future Oncol
7(10):1223–1235
6. Silva MT (2010) Secondary necrosis: the natural outcome of the
complete apoptotic program. FEBS Lett 584(22):4491–4499
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford
R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L,
Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New
response evaluation criteria in solid tumours: Revised RECIST
guideline (version 1.1). Eur J Cancer 45(2):228–247
8. Abdulla S, Saada J, Johnson G, Jefferies S, Ajithkumar T (2015)
Tumour progression or pseudoprogression? A review of post-
treatment radiological appearances of glioblastoma. Clin Radiol
70(11):1299–1312
9. Xie B, Stammes MA, van Driel PBAA, Cruz LJ, Knol-Blankevoort
VT, Löwik MAM, Mezzanotte L, Que I, Chan A, van den Wijngaard
JPHM, Siebes M, Gottschalk S, Razansky D, Ntziachristos V,
Keereweer S, Horobin RW, Hoehn M, Kaijzel EL, van Beek ER,
Snoeks TJA, Löwik CWGM (2015) Necrosis avid near infrared
fluorescent cyanines for imaging cell death and their use to monitor
therapeutic efficacy in mouse tumor models. Oncotarget 6(36):39036–
39049
10. Xie B, Tomaszewski MR, Neves AA, Ros S, Hu DE, McGuire S,
Mullins SR, Tice D, Sainson RCA, Bohndiek SE, Wilkinson RW,
Brindle KM (2017) Optoacoustic detection of early therapy-induced
tumor cell death using a targeted imaging agent. Clin Cancer Res
23(22):6893–6903
11. Stammes MA, Maeda A, Bu J et al (2016) The necrosis-avid small
molecule HQ4-DTPA as a multimodal imaging agent for monitoring
radiation therapy-induced tumor cell death. Front Oncol 6:221
12. Salah S, Lewin J, Amir E, Abdul Razak A (2018) Tumor necrosis and
clinical outcomes following neoadjuvant therapy in soft tissue
sarcoma: a systematic review and meta-analysis. Cancer Treat Rev
69:1–10
13. Cona M, Li J, Feng Y, Chen F, Verbruggen A, Witte P, Oyen R, Ni Y
(2014) Targetability and biodistribution of radioiodinated hypericin:
comparison between microdosing and carrier-added preparations. Anti
Cancer Agents Med Chem 14(6):852–861
14. Abma E, Peremans K, De Vos F et al (2018) Biodistribution and
tolerance of intravenous iodine-131-labelled hypericin in healthy
dogs. Vet Comp Oncol 16(3):318–323
15. Jiang B, Wang J, Ni Y, Chen F (2013) Necrosis avidity: a newly
discovered feature of hypericin and its preclinical applications in
necrosis imaging. Theranostics 3(9):667–676
16. Ji Y, Zhan Y, Jiang C, Jiang X, Gao M, Liu W, Li Y, Wang J, Wang
Q, Cona MM, Yao N, Wang X, Fang Z, Yin Z, Zhang J, Sun Z, Ni Y
(2014) Improvement of solubility and targetability of radioiodinated
hypericin by using sodium cholate based solvent in rat models of
necrosis. J Drug Target 22(4):304–312
17. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P (2002) St
John’s wort (Hypericum perforatum): drug interactions and clinical
outcomes. Br J Clin Pharmacol 54(4):349–356
18. Camera L, Kinuya S, Garmestani K, Wu C, Brechbiel MW, Pai LH,
McMurry T, Gansow OA, Pastan I, Paik CH (1994) Evaluation of the
serum stability and in vivo biodistribution of CHX-DTPA and other
ligands for yttrium labeling of monoclonal antibodies. J Nucl Med
35(5):882–889
19. Zhao J, Chen J, Ma S, Liu Q, Huang L, Chen X, Lou K, Wang W
(2018) Recent developments in multimodality fluorescence imaging
probes. Acta Pharm Sin B 8(3):320–338
20. Hernandez R, Heskamp S, Rijpkema M, Bos DL, Goldenberg DM,
McBride WJ, Morgenstern A, Bruchertseifer F, Cai W, Boerman OC
(2017) Preventing radiobleaching of cyanine fluorophores enhances
stability of nuclear/NIRF multimodality imaging agents. Theranostics
7(1):1–8
21. Stammes MA, Knol-Blankevoort VT, Cruz LJ, Feitsma HRIJ,
Mezzanotte L, Cordfunke RA, Sinisi R, Dubikovskaya EA, Maeda
A, DaCosta RS, Bierau K, Chan A, Kaijzel EL, Snoeks TJA, van
Beek ER, Löwik CWGM (2016) Pre-clinical evaluation of a cyanine-
based SPECT probe for multimodal tumor necrosis imaging. Mol
Imaging Biol 18(16):905–915
22. Keller T, López-Picón FR, Krzyczmonik A, Forsback S, Takkinen JS,
Rajander J, Teperi S, Dollé F, Rinne JO, Haaparanta-Solin M, Solin O
(2019) Comparison of high and low molar activity TSPO tracer
[(18)F]F-DPA in a mouse model of Alzheimer’s disease. J Cereb
Blood Flow Metab 40:1012–1020. https://doi.org/10.1177/
0271678x19853117
23. van Manen L, Handgraaf HJM, Diana M, Dijkstra J, Ishizawa T,
Vahrmeijer AL, Mieog JSD (2018) A practical guide for the use of
indocyanine green and methylene blue in fluorescence-guided
abdominal surgery. J Surg Oncol 118(2):283–300
24. Marshall MV, Draney D, Sevick-Muraca EM, Olive DM (2010)
Single-dose intravenous toxicity study of IRDye 800CW in Sprague-
Dawley rats. Mol Imaging Biol 12(6):583–594
25. Rosenthal EL, Warram JM, De Boer E et al (2015) Safety and tumor
specificity of cetuximab-IRDye800 for surgical navigation in head and
neck cancer. Clin Cancer Res 21(16):3658–3666
26. Price EW, Orvig C (2014) Matching chelators to radiometal for
radiopharmaceuticals. Chem Soc Rev 43(1):260–290
Publisher’s Note. Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Stroet M.C.M. et al.: In Vivo Evaluation of Indium-111–Labeled 800CW as a Necrosis-Avid Contrast Agent
